Long-term shareholder Baillie Gifford has thrown its support behind CoStar Group as the real estate data provider faces mounting pressure from activist hedge funds led by Third Point and DE Shaw, according to a report by Bloomberg.
Ken Griffin’s multi-strategy hedge fund major Citadel has appointed AJ Bolduc, formerly of Goldman Sachs, to head Asia trading and equity capital markets within its International Equities team in Hong Kong, according to a report by Bloomberg.
UK industry figures have urged the Financial Conduct Authority to intervene over what they describe as repeated and disruptive board challenges by Saba Capital targeting British investment trusts, according to a report by This Is Money.
Hedge funds significantly increased bearish bets against Hims & Hers Health in January, just weeks before the online healthcare provider became embroiled in a legal and regulatory dispute with Novo Nordisk, according to a report by Reuters citing data from
SGX FX has announced a strategic integration with CME Group’s EBS Market and FX Spot+ platform, aiming to deliver enhanced connectivity, liquidity, and execution options for global forex market participants.
Tycho Capital has launched a new UCITS vehicle in partnership with London-based CapeView Capital, the Tycho CapeView European Long Short Fund, which debuted with over $40m in investor commitment and is targeting European equity long-short strategies.
Leading hedge funds, including Point72, King Street Capital, Millennium and Schonfeld, are establishing standalone private credit businesses as investor appetite for the fast-growing asset class continues to surge, according to a report by Financial News London.
Global hedge fund portfolios showed signs of heightened volatility in January amid ongoing geopolitical tensions, major policy shifts, and energy market swings, according to the latest Crowdedness Report from Hazeltree.
Hedge funds are entering 2026 with strong momentum after delivering double-digit returns last year and exceeding allocator expectations, according to a new survey by Goldman Sachs of pension funds, family offices, funds of funds, and other pools of capital.
Most life sciences and biopharma hedge funds started 2026 on the back foot, giving up ground in January after one of the strongest years on record for the sector with the pull-back coming despite a 2.5% gain in the Nasdaq
